January 2015

New Product - Rosuzet Composite Pack

Rosuzet Composite Pack (ezetimibe, rosuvastatin) is indicated in primary hypercholesterolaemia (adjunct to diet, where combination treatment appropriate) and in homozygous familial hypercholesterolaemia (HoFH). Rosuzet Composite Pack is contraindicated in patients with myopathy secondary to other lipid lowering drugs; active liver disease including unexplained persistent raised serum transaminases more than three times the upper limit of normal; gall bladder disease (+ fenofibrate); concomitant fusidic acid (within 7 days); women of childbearing potential (unless with adequate contraception); in pregnancy and lactation. Rosuzet 10 mg + 40 mg dose is also contraindicated in myopathy/ rhadomyolysis predisposition including hypothyroidism, hereditary muscular disorder history (including family history), previous muscular toxicity with other HMG-CoA reductase inhibitors, fibrate, alcohol abuse, situations where rosuvastatin plasma levels may increase, severe renal impairment (creatinine clearance less than 30 mL/minute), Asian descent and with concomitant fibrates. Rosuzet Composite Pack is available as Rosuzet 10 mg + 5 mg containing ezetimibe 10 mg (30’s) and MSD rosuvastatin 5 mg (30’s); Rosuzet 10 mg + 10 mg containing ezetimibe 10 mg (30’s) and MSD rosuvastatin 10 mg (30’s); Rosuzet 10 mg + 20 mg containing ezetimibe 10 mg (30’s) and MSD rosuvastatin 20 mg (30’s); and Rosuzet 10 mg + 40 mg containing ezetimibe 10 mg (30’s) and MSD rosuvastatin 40 mg (30’s).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629